Safety and Efficacy Evaluation of Topical Moxidex Otic Solution Compared to Moxifloxacin Solution in the Treatment of Acute Otitis Media with Otorrhea through Tympanostomy Tubes (AOMT) (2005-current). Principal Investigator: Gary Josephson. MD. Sub-Investigator: Laurie Duckworth PhD, ARNP
The Study of Acid Reflux in Children with Asthma (SARCA) (2006-2008). Principal Investigator: John Lima, PharmD. Sub-Investigator: Laurie Duckworth, PhD, ARNP.
Vestibular Deficits and related impairments in children with otitis media with effusion (2008). Principal Investigator: Gary Josephson, MD. Sub-Investigator: Laurie Duckworth, PhD, ARNP
Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children: (2007-present). Sponsor: American Diabetes Association
Principal Investigator: Amanda Lochrie, PhD. Study Coordinator: Laurie Duckworth, PhD, ARNP.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Study Evaluating the Efficacy and Safety of ALTU-135 Treatment in Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency. Altus Protocol #0000726. (2007-present). Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, PhD, ARNP.
A Phase III, Open-Label Clinical Study Evaluating the Long-Term Safety and Clinical Activity of ALTU-135 for the Treatment of Patients with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency. Altus Protocol #0000767. (2007-present). Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, PhD, ARNP
Study of Acid Reflux and Asthma (SARA) (2004-current). Principal Investigator: John Lima, Pharm.D. Sub-Investigator: Laurie Duckworth, PhD, ARNP
Effect of Simple Obesity on Lung Function in Children. (2007). Principal Investigator: Jason Lang, MD. Sub-Investigator: Laurie Duckworth, PhD, ARNP
A Multi-Center, Double-Blind, Placebo-Controlled Randomized, Efficacy and Safety Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients with Mild Cystic Fibrosis Lung Disease. Protocol: Inspire 08-108 (TIGER-1). (2007). Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, MSN, ARNP
A randomized, double-blind, double-dummy parallel group study evaluating the safety of fluticasone propionate/salmeterol 100/50mcg HFA (2 inhalations of 50/25mcg) twice daily compared with fluticasone propionate 100mcg HFA (2 inhalations of 50mcg) twice daily in subjects 4-11 years of age with persistent asthma. Protocol SFA106484. (2006-2007). Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, MSN, ARNP
A repeat-dose, open-label, randomized, incomplete block design in pediatric subjects with asthma, ages 4 - 11 years, to compare systemic exposure and pharmacodynamics of fluticasone propionate and salmeterol following Advair HFA 45/21mcg (2 inhalations), ADVAIR HFA 45/21mcg (2 inhalations) with Aerochamber Plus Spacer and Advair Diskus 100/50 twice daily. Protocol: SAS105519. (2007). Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, MSN, ARNP
A repeat-dose, open-label, 2-session study to assess the systemic exposure to, and pharmacodynamics of, fluticasone propionate HFA inhalation aerosol 88mcg administered twice-daily for 28 days delivered via an MDI and valved holding chamber with facemask to subjects ages 6 months to 12. Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, MSN, ARNP.
A Randomized, Double-Blind, Placebo-Controlled Two-Treatment Crossover Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) in Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency Protocol: EUR-1008-M. (> 7 years of age). (2006-2007). Principal Investigator: David Schaffer, MD. Sub-Investigator: Laurie Duckworth, MSN, ARNP.
An Open-Label Study to Evaluate the Safety and Efficacy of Eurand Pancreatic Enzyme Product (PEP) Microtabs in Pediactric Patients with Cystic Fibrosis and Exocrine Pancreatic Insufficiency Protocol: EUR-1009-M. (< 7 years of age) (2006-2007). Principal Investigator: David Schaffer, MD. Sub-Investigator: Laurie Duckworth, MSN, ARNP
Sinusitis and Rhinitis in Asthma (SIRNA), American Lung Association, (2005-2006). Principal Investigator: John Lima, Pharm.D. Sub-Investigator: Laurie Duckworth, MSN, ARNP
A Phase 3, Open-Label, Follow-on Study of Multiple Courses of Aztreonam Lysinate for Inhalation (AI) in Cystic Fibrosis Patients (AIR-CF3). Protocol CP-AI-006 (2005-2006). Principal Investigator: David Schaffer, MD. Sub-Investigator: Laurie Duckworth, MSN, ARNP.
The Leukotriene Modifier or Corticosteroids or Corticosteroid-Salmeterol Trial (The LOCCS Trial) (2003-2005). Principal Investigator: John Lima, Pharm.D. Sub-Investigator: Laurie Duckworth, MSN, ARNP.
Polymorphisms of Nitric Oxide Synthase Genes in Sickle Cell Patients with Acute Chest Syndrome. (2001-2004). Principal Investigator: John Lima PharmD. Sub-Investigator: Laurie Duckworth, ARNP, MSN.
A Randomized, Open-label, Multicenter, Phase 3 Trial to Assess the Safety of Tobramycin Inhalation Powder (TIP) Compared to TOBI® in Cystic Fibrosis (CF) Subjects. Protocol CTBM100C2302. Principal Investigator: David Schaffer, MD. Co-Investigator: Laurie Duckworth, MSN, ARNP.
A Pilot Project Exploring the Feasibility of Using Remote Monitoring to PromoteTransition Readiness in Adolescents with Spina Bifida. Co-Investigator. NCCJ. 2008) Kim Jarczyk, MSN, ARNP.
Physical and Mental Health Benefits of Dance in Visually Impaired Adolescents. Co-Investigator. University of Florida College of Medicine. (2005-present) Kim Jarczyk, MSN, ARNP.
Development and initial use of the diabetes support in school scale, funded by Nemours Biomedical Research, May 2007. Principal Investigator: Doreen Radjenovic, PhD, ARNP
Northeast Florida school nurse study, funded by the University of North Florida College of Health. May 2005. Co-investigator: Doreen Radjenovic, PhD, ARNP.
Camp intervention for teens with type 2 diabetes, funded by the University of North Florida College of Health, May 2004. Co-investigator: Doreen Radjenovic, PhD, ARNP.